How to manage zolbetuximab extravasation?

Published

There is no specific guidance for managing zolbetuximab extravasation

In the SPOTLIGHT and GLOW Phase 3 trials, extravasation occurred in 0.9% (10/1060) of all patients.1 Four out of the ten cases reported were attributed to concomitant chemotherapy agents (fluorouracil or oxaliplatin), with no cases reported by investigators as related to zolbetuximab.

  • Zolbetuximab’s extravasation risk is unclassified.1
  • Local tolerance at injection sites was assessed in mice for 13 weeks and in cynomolgus monkeys for 4 weeks, with no reactions related to zolbetuximab observed during daily macroscopic or histopathological evaluations.1 

  1. Data on File.

find-my-msl

Find My MSL

Medical Science Liaisons are available to help answer your scientific questions.

submit

Submit an Inquiry

For any medical inquiries, please submit your question online to Astellas Medical Information or call or fax your inquiry.

Astellas Phone: 1-800-727-7003

Fax: 1-877-829-7942

adverse

Report an Adverse Event or Product Complaint

Report adverse events and product complaints to Astellas or FDA MedWatch.

Astellas Phone: 1-800-727-7003

FDA MedWatch: 1-800-FDA-1088

Hours: M–F, 8 AM–4:30 PM (CT)